JP2021505527A - 神経変性疾患の予防及び/又は治療 - Google Patents
神経変性疾患の予防及び/又は治療 Download PDFInfo
- Publication number
- JP2021505527A JP2021505527A JP2020521460A JP2020521460A JP2021505527A JP 2021505527 A JP2021505527 A JP 2021505527A JP 2020521460 A JP2020521460 A JP 2020521460A JP 2020521460 A JP2020521460 A JP 2020521460A JP 2021505527 A JP2021505527 A JP 2021505527A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- omega
- lutein
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002265 prevention Effects 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 230000004770 neurodegeneration Effects 0.000 title description 3
- 208000015122 neurodegenerative disease Diseases 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 122
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 70
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims abstract description 63
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims abstract description 63
- 229960005375 lutein Drugs 0.000 claims abstract description 42
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 42
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 42
- 206010012289 Dementia Diseases 0.000 claims abstract description 41
- 235000012680 lutein Nutrition 0.000 claims abstract description 41
- 239000001656 lutein Substances 0.000 claims abstract description 41
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 41
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 41
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 37
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 37
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 37
- 235000020674 meso-zeaxanthin Nutrition 0.000 claims abstract description 35
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims abstract description 28
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims abstract description 28
- 235000010930 zeaxanthin Nutrition 0.000 claims abstract description 28
- 239000001775 zeaxanthin Substances 0.000 claims abstract description 28
- 229940043269 zeaxanthin Drugs 0.000 claims abstract description 28
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 23
- 208000024827 Alzheimer disease Diseases 0.000 claims description 61
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 61
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 35
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 29
- 235000021323 fish oil Nutrition 0.000 claims description 22
- 208000024891 symptom Diseases 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 15
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 14
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 13
- 208000010877 cognitive disease Diseases 0.000 claims description 13
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 13
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003086 colorant Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- 235000001055 magnesium Nutrition 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 claims description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims description 2
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 claims description 2
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 claims description 2
- 244000017106 Bixa orellana Species 0.000 claims description 2
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 claims description 2
- 240000004160 Capsicum annuum Species 0.000 claims description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims description 2
- 244000124209 Crocus sativus Species 0.000 claims description 2
- 235000015655 Crocus sativus Nutrition 0.000 claims description 2
- 244000163122 Curcuma domestica Species 0.000 claims description 2
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 239000001692 EU approved anti-caking agent Substances 0.000 claims description 2
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 claims description 2
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 235000012665 annatto Nutrition 0.000 claims description 2
- 239000010362 annatto Substances 0.000 claims description 2
- 235000012677 beetroot red Nutrition 0.000 claims description 2
- 239000001654 beetroot red Substances 0.000 claims description 2
- 235000002185 betanin Nutrition 0.000 claims description 2
- 235000012745 brilliant blue FCF Nutrition 0.000 claims description 2
- 239000004161 brilliant blue FCF Substances 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 239000000378 calcium silicate Substances 0.000 claims description 2
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 2
- 239000001511 capsicum annuum Substances 0.000 claims description 2
- 235000013736 caramel Nutrition 0.000 claims description 2
- 235000012730 carminic acid Nutrition 0.000 claims description 2
- 239000004106 carminic acid Substances 0.000 claims description 2
- UQWIHFJXDRNUDP-UHFFFAOYSA-N chembl1206007 Chemical compound COC1=CC(S(O)(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S(O)(=O)=O)=CC=C12 UQWIHFJXDRNUDP-UHFFFAOYSA-N 0.000 claims description 2
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 claims description 2
- 229940080423 cochineal Drugs 0.000 claims description 2
- 235000003373 curcuma longa Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 235000012732 erythrosine Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 235000013974 saffron Nutrition 0.000 claims description 2
- 239000004248 saffron Substances 0.000 claims description 2
- 235000012217 sodium aluminium silicate Nutrition 0.000 claims description 2
- 239000000429 sodium aluminium silicate Substances 0.000 claims description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 2
- KVMUSGMZFRRCAS-UHFFFAOYSA-N sodium;5-oxo-1-(4-sulfophenyl)-4-[(4-sulfophenyl)diazenyl]-4h-pyrazole-3-carboxylic acid Chemical compound [Na+].OC(=O)C1=NN(C=2C=CC(=CC=2)S(O)(=O)=O)C(=O)C1N=NC1=CC=C(S(O)(=O)=O)C=C1 KVMUSGMZFRRCAS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- DCXPBOFGQPCWJY-UHFFFAOYSA-N trisodium;iron(3+);hexacyanide Chemical compound [Na+].[Na+].[Na+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCXPBOFGQPCWJY-UHFFFAOYSA-N 0.000 claims description 2
- 235000013976 turmeric Nutrition 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 4
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims 1
- 239000004097 EU approved flavor enhancer Substances 0.000 claims 1
- 235000019264 food flavour enhancer Nutrition 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 23
- 239000013589 supplement Substances 0.000 description 15
- 239000006014 omega-3 oil Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 235000001412 Mediterranean diet Nutrition 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000003920 cognitive function Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000001149 cognitive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 3
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000006999 cognitive decline Effects 0.000 description 3
- 230000003931 cognitive performance Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 235000009337 Spinacia oleracea Nutrition 0.000 description 2
- 244000300264 Spinacia oleracea Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036995 brain health Effects 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000020988 fatty fish Nutrition 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 2
- 229940025508 lutein / zeaxanthin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 235000018343 nutrient deficiency Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- VBCVPMMZEGZULK-NRFANRHFSA-N indoxacarb Chemical compound C([C@@]1(OC2)C(=O)OC)C3=CC(Cl)=CC=C3C1=NN2C(=O)N(C(=O)OC)C1=CC=C(OC(F)(F)F)C=C1 VBCVPMMZEGZULK-NRFANRHFSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 238000011302 passive avoidance test Methods 0.000 description 1
- 239000002530 phenolic antioxidant Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 235000021413 well-balanced diet Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
(i)L、Z及びMZの血清濃度;
(ii)0.23度の網膜偏心度(「MP0.23」)における黄斑中の黄斑色素(MP)濃度(説明については下記参照);
(iii)MP量(曲線下MP量)(下記参照);
(iv)LPC22:6及びLPC20:5(これらは、それぞれDHA又はEPAのいずれかを含有する血液中のリン脂質の尺度である−下記参照);並びに
(v)認知症の医学的評価(+/−「MMSE」)。これらの特徴についてのベースライン値を以下の表1に示す。
生化学的応答:
生化学的評価のため、試料をベースラインにおいて、及びさらにはサプリメント摂取の6ヵ月後に得た。血清MZ、L及びZ濃度を血漿の高速液体クロマトグラフィー(HPLC)により評価した。DHA及びEPAのマーカーを、上記詳述の既に検証された方法を使用する血液試料の液体クロマトグラフィー(LC)質量分析(MS)メタボロミクス及びリピドミクス分析により評価した。
これは担当臨床医の監視下で実施し、有効な技術である。MMSEの結果を使用して患者リクルートメントの間にADの診断を手引きした。AD状態を以下のとおり定義した:MMSEスコア0〜10=重度AD;MMSEスコア11〜20=中等度AD;MMSEスコア21〜25=軽度AD;26+=ADなし。試験の開始時に実施されたMMSEに加え、それぞれの患者を健康及びAD状態について可能であれば18ヵ月間評価した。
黄斑カロテノイドレベル
最初に、試験2対象における平均血清ルテイン濃度(0.154±0.084μmol/L)は、対照群(0.297±0.179)よりもかなり低かったことを留意すべきであり、この差は、独立標本T検定により決定して統計的に有意であった(p=0.010)。
血清DHA(黒色丸)及び血清EPA(白色丸)についての結果を、ベースライン及び6ヵ月後の試験群2対象について図4に示す。EPA濃度が増加し、DHAの濃度はかなり顕著に増加したことを確認することができる。試験において使用された魚油サプリメントがEPAよりも多いDHAを含有したため、DHAレベルのより大きい応答が予測することができた。
患者の医学的評価をベースライン及びサプリメント摂取の18ヵ月後に実施した。医学的評価を医療コンサルタントの監視下で有資格AD看護師により実施した。さらに、患者がサプリメント摂取して18ヵ月後に患者介護者に面接した。ベースラインにおけるAD状態を医療コンサルタントにより確認した。
本明細書に提供される実施例は、ADが栄養素欠乏疾患であり得ることを示唆する。当該栄養素は、ヒト脳中で同定されているカロテノイド(ルテイン及びゼアキサンチン)及びDHAである。これらの栄養素は、それらの酸化防止、抗炎症、及び構造的役割を介して脳の健康を支援し、ADのリスクを低減させる潜在性を有する。本発明者らは、ADが栄養素欠乏疾患であること、及び本試験において観察された好ましい医学的応答はこの欠乏の補正に起因することを仮定する。しかしながら、疾患が発症している状況において、栄養素欠乏の補正は疾患を回復させ得ず;しかし、脳の健康及び機能の安定化が達成され、カロテノイド及び魚油が補給された患者におけるAD進行の停止と一致する。
参照文献:
[1]Alzheimer’s Association(2017)2017 Alzheimer’s disease facts and figures,Alzheimer’s Association,Chicago,IL,USA.
[2]Tangney et al.,(2011)Adherence to a Mediterranean−type dietary pattern and cognitive decline in a community population.Am J Clin Nutr 93,601−607.
[3]Feart et al.,(2009)Adherence to a Mediterranean diet,cognitive decline,and risk of dementia.J.A.M.A.302,638−648.
[4]Trichopoulou et al.,(2015)Mediterranean diet and cognitive decline over time in an elderly Mediterranean population.Eur.J Nutr.54, 1311−1321.
[5]Pelletier et al.,(2015)Mediterranean diet and preserved brain structural connectivity in older subjects.Alzheimers Dement 11,1023−1031.
[6]McEvoy et al.,(2017)Neuroprotective Diets Are Associated with Better Cognitive Function:The Health and Retirement Study.J Am Geriatr Soc 65,1857−1862.
[7]Lourida et al.,(2013)Mediterranean diet,cognitive function,and dementia:a systematic review.Epidemiology 24,479−489.
[8]Psaltopoulou et al.,(2013)Mediterranean diet,stroke,cognitive impairment,and depression:A meta−analysis.Ann Neurol 74,580−591.
[9]Singh et al.,(2014)Association of mediterranean diet with mild cognitive impairment and Alzheimer’s disease:a systematic review and meta−analysis.J Alzheimers Dis 39,271−282.
[10]Scarmeas et al.,(2006)Mediterranean diet and risk for Alzheimer’s disease.Ann Neurol 59,912−921.
[11]Scarmeas et al.,(2009)Mediterranean diet and mild cognitive impairment.Arch Neurol 66,216−225.
[12]Sofi et al.,(2014)Mediterranean diet and health status:an updated meta−analysis and a proposal for a literature−based adherence score.Public Health Nutr 17,2769−2782.
[13]Muldoon et al.,(2014)Long−chain omega−3 fatty acids and optimization of cognitive performance.Mil Med 179,95−105.
[14]Cole et al.,(2005)Prevention of Alzheimer’s disease:Omega−3 fatty acid and phenolic anti−oxidant interventions.Neurobiol Aging 26 Suppl 1,133−136.
[15]Fotuhi et al.,(2009)Fish consumption,long−chain omega−3 fatty acids and risk of cognitive decline or Alzheimer disease:a complex association.Nat Clin Pract Neurol 5,140−152.
[16]Thomas et al.,(2015)Omega−3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease:A Focus on Alzheimer’s Disease.Biomed Res Int 2015,172801.
[17]Cole&Frautschy et al.,(2010)DHA may prevent age−related dementia.J Nutr 140,869−874.
[18]Abubakari AR,Naderali MM,Naderali EK(2014)Omega−3 fatty acid supplementation and cognitive function:are smaller dosages more beneficial? Int J Gen Med 7,463−473.
[19]Yurko−Mauro et al.,(2010)Beneficial effects of docosahexaenoic acid on cognition in age−related cognitive decline.Alzheimers Dement 6,456−464.
[20]Phillips et al.,(2015)No Effect of Omega−3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer’s Disease:A Randomised Controlled Trial.Int J Mol Sci 16,24600−24613.
[21]van de Rest et al.,(2008)Effect of fish oil on cognitive performance in older subjects:a randomized,controlled trial.Neurology 71,430−438.
[22]Perry et al.,(2009)Xanthophyll(lutein,zeaxanthin)content in fruits,vegetables and corn and egg products.Journal of Food Composition and Analysis 22, 9−15.
[23]Johnson et al.,(2013)Relationship between Serum and Brain Carotenoids,alpha−Tocopherol, and Retinol Concentrations and Cognitive Performance in the Oldest Old from the Georgia Centenarian Study.J Aging Res 2013,951786.
[24]Craft et al.,(2004)Carotenoid,tocopherol,and retinol concentrations in elderly human brain.J Nutr Health Aging 8,156−162.
[25]Feart et al.,(2016)Plasma Carotenoids Are Inversely Associated With Dementia Risk in an Elderly French Cohort. J Gerontol A Biol Sci Med Sci 71, 683−688.
[26]Min&Min(2014)Serum lycopene,lutein and zeaxanthin,and the risk of Alzheimer’s disease mortality in older adults.Dement Geriatr Cogn Disord 37,246−256.
[27]Loef&Walach(2012)Fruit,vegetables and prevention of cognitive decline or dementia: a systematic review of cohort studies. J Nutr Health Aging 16,626−630.
[28]Hammond et al.,(2017)Effects of Lutein/Zeaxanthin Supplementation on the Cognitive Function of Community Dwelling Older Adults:A Randomized,Double−Masked,Placebo−Controlled Trial.Front Aging Neurosci 9,254.
[29]Johnson et al.,(2008)Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women.Nutr Neurosci 11,75−83.
[30]Chew et al.,Age−Related Eye Disease Study 2 Research G(2015)Effect of Omega−3 Fatty Acids,Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function:The AREDS2 Randomized Clinical Trial.JAMA 314,791−801.
[31]Mangialasche et al.,(2010)High plasma levels of vitamin E forms and reduced Alzheimer’s disease risk in advanced age.J Alzheimers Dis 20,1029−1037.
[32]Livingstone et al.,(2017)Dementia prevention,intervention, and care.Lancet 390,2673−2734.
Claims (26)
- ヒト対象における認知症の予防及び/又は治療の使用のための;ルテイン、ゼアキサンチン及びメソゼアキサンチンからなる群から選択される少なくとも1つのカロテノイドを含む組成物;並びに少なくとも1つのオメガ−3脂肪酸を含む組成物。
- ルテイン、ゼアキサンチン及びメソゼアキサンチンのそれぞれを含む、請求項1に記載の組成物。
- 単一組成物が、ルテイン、ゼアキサンチン、メソゼアキサンチンのそれぞれ及び少なくとも1つのオメガ−3脂肪酸を含む、請求項1又は2に記載の組成物。
- 前記少なくとも1つのオメガ−3脂肪酸が、ドコサヘキサエン酸を含む、請求項1〜3のいずれか一項に記載の組成物。
- 前記少なくとも1つのオメガ−3脂肪酸が、前記組成物中の魚油構成成分として提供される、請求項1〜4のいずれか一項に記載の組成物。
- 前記少なくとも1つのオメガ−3脂肪酸が、少なくとも2つの脂肪酸を含む、請求項1〜5のいずれか一項に記載の組成物。
- 前記オメガ−3脂肪酸含有組成物が、ドコサヘキサエン酸及びエイコサペンタエン酸を含む、請求項1〜6のいずれか一項に記載の組成物。
- 前記少なくとも1つのオメガ−3脂肪酸が、遊離酸として、塩として又はトリグリセリドとして提供される、請求項1〜7のいずれか一項に記載の組成物。
- 前記塩が、モノカチオン、好ましくは、金属モノカチオンを含む、請求項8に記載の組成物。
- アルツハイマー病の予防及び/又は治療における使用のための、請求項1〜9のいずれか一項に記載の組成物。
- 前記組成物が、経口摂取に好適であるように配合され、経口投与される、請求項1〜10のいずれか一項に記載の組成物。
- 前記組成物が、少なくとも週2回、好ましくは、少なくとも週3回、最も好ましくは、1日1回投与される、請求項1〜11のいずれか一項に記載の組成物。
- 前記組成物が、単位用量形態である、請求項1〜12のいずれか一項に記載の組成物。
- 組成物のそれぞれの単位用量が、10mgのメソゼアキサンチン、10mgのルテイン、2mgのゼアキサンチン、及び魚油、好ましくは、1gmの魚油を含む、請求項13に記載の組成物。
- 組成物のそれぞれの単位用量が、15mgのメソゼアキサンチン、5mgのルテイン、1mgのゼアキサンチン、及び魚油、好ましくは、1gmの魚油を含む、請求項13に記載の組成物。
- 前記組成物のそれぞれの単位用量が、20mg〜2グラムのドコサヘキサエン酸を含む、請求項13に記載の組成物。
- 前記組成物が、以下の1つ以上:酸性度調節剤;固化防止剤、例として、アルミノケイ酸ナトリウム、炭酸カルシウム又はマグネシウム、ケイ酸カルシウム、フェリシアン化ナトリウム又はカリウム;酸化防止剤、例として、ビタミンE、ビタミンC、及びポリフェノール;着色料、例として、人工着色料、FD&Cの青色1号、青色2号、緑色3号、赤色40号、赤色3号、黄色5号及び黄色6号;並びに天然着色料のカラメル、アナトー、コチニール、ベタニン、ターメリック、サフラン、パプリカ;保色剤;乳化剤;フレーバー;フレーバー増強剤;保存剤;安定剤;甘味剤並びに増粘剤をさらに含む、請求項1〜16のいずれか一項に記載の組成物。
- 前記組成物が、錠剤又はカプセル剤の形態である、請求項1〜17のいずれか一項に記載の組成物。
- 前記対象が、前記組成物を少なくとも6ヵ月、好ましくは、少なくとも12ヵ月、最も好ましくは、少なくとも18ヵ月の期間にわたり週1回又は1日1回摂取する、請求項1〜18のいずれか一項に記載の組成物。
- 前記対象が、前記組成物の最初の投与前にアルツハイマー病の1つ以上の症状を既に呈する、請求項1〜19のいずれか一項に記載の組成物。
- 前記組成物が、前記対象がアルツハイマー病の任意の症状を呈する前に前記対象に最初に投与される、請求項1〜19のいずれか一項に記載の組成物。
- 実質的にルテイン、ゼアキサンチン、メソゼアキサンチン、少なくとも1つのオメガ−3多価不飽和脂肪酸又は対応する塩若しくはトリグリセリド、及び希釈剤、担体又は賦形剤からなる組成物の使用を含む、請求項1〜21のいずれか一項に記載の組成物。
- 前記オメガ−3多価不飽和脂肪酸又は対応する塩若しくはトリグリセリドが、DHA又はDHAの塩若しくはトリグリセリドである、請求項22に記載の組成物。
- ルテイン、ゼアキサンチン、メソゼアキサンチンのそれぞれ並びにDHA及び/又はEPAを含み、1日1回の経口投与のための単位用量形態で配合され、前記組成物の投与前にアルツハイマー病の1つ以上の症状を既に呈する対象における認識機能障害の進行の予防又は遅延における使用のための、請求項1〜23のいずれか一項に記載の組成物。
- ヒト対象における認知症、特にアルツハイマー病を予防及び/又は治療する方法であって、前記対象に、ルテイン、ゼアキサンチン及びメソゼアキサンチンからなる群から選択される黄斑カロテノイドを含む有効量の組成物;並びに少なくとも1つのオメガ−3脂肪酸を含む有効量の組成物を投与するステップを含む方法。
- 請求項1〜24のいずれか一項に記載の組成物の使用を含む、請求項25に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1720119.5A GB201720119D0 (en) | 2017-12-04 | 2017-12-04 | Prevention and/or treatment of neurodegenerative disease |
GB1720119.5 | 2017-12-04 | ||
PCT/GB2018/051255 WO2019110951A1 (en) | 2017-12-04 | 2018-05-10 | Prevention and/or treatment of neurodegenerative disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021505527A true JP2021505527A (ja) | 2021-02-18 |
JP2021505527A5 JP2021505527A5 (ja) | 2021-07-26 |
Family
ID=60950313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020521460A Pending JP2021505527A (ja) | 2017-12-04 | 2018-05-10 | 神経変性疾患の予防及び/又は治療 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10835509B2 (ja) |
EP (1) | EP3644979A1 (ja) |
JP (1) | JP2021505527A (ja) |
KR (1) | KR20200095452A (ja) |
AU (1) | AU2018379644B2 (ja) |
BR (1) | BR112020005132A2 (ja) |
CA (1) | CA3071786C (ja) |
GB (2) | GB201720119D0 (ja) |
IE (1) | IE87241B1 (ja) |
MX (1) | MX2020002458A (ja) |
RU (1) | RU2020111305A (ja) |
SG (1) | SG11202000786RA (ja) |
WO (1) | WO2019110951A1 (ja) |
ZA (1) | ZA202000558B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022244727A1 (ja) * | 2021-05-17 | 2022-11-24 | 小野薬品工業株式会社 | 認知機能を改善するための組成物 |
WO2024143060A1 (ja) * | 2022-12-26 | 2024-07-04 | サントリーホールディングス株式会社 | 脳神経細胞保護用組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3106957B1 (fr) * | 2020-02-07 | 2024-05-03 | Abdelhadi Zahouani | Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris |
US12076299B2 (en) * | 2020-02-20 | 2024-09-03 | Arjuna Natural Pvt Ltd | Composition and method to enhance cognitive support and brain health |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006116755A2 (en) * | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
WO2014106741A1 (en) * | 2013-01-03 | 2014-07-10 | Howard Foundation Holdings Ltd | Identifying subjects in need of treatment |
JP2014524914A (ja) * | 2011-07-07 | 2014-09-25 | ハワード・ファウンデーション・ホールディングス・リミテッド | 視覚パフォーマンス及び/若しくは黄斑色素形成の改善、又は視覚パフォーマンス及び/若しくは黄斑色素形成に関連した改善 |
WO2015005443A1 (ja) * | 2013-07-10 | 2015-01-15 | ライオン株式会社 | 内服組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006121421A2 (en) | 2004-01-14 | 2006-11-16 | Robert Ritch | Methods and formulations for treating glaucoma |
US8324276B2 (en) * | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
WO2009078716A1 (en) * | 2007-12-17 | 2009-06-25 | Newtricious B.V. | Method of producing egg yolk based functional food product and products obtainable thereby |
GB201014340D0 (en) | 2010-08-27 | 2010-10-13 | Piraee Mahmood | Nutritional supplement formulation comprising saffron and resveratrol |
SG11201500379QA (en) * | 2012-07-19 | 2015-03-30 | Us Nutraceuticals Llc Dba Valensa Int | Krill oil and reacted astaxanthin composition and associated method |
US20140187648A1 (en) * | 2013-01-03 | 2014-07-03 | Howard Foundation Holdings Ltd. | Identifying Subjects in Need of Treatment |
SG11201507973TA (en) * | 2013-03-28 | 2015-10-29 | Omniactive Health Technologies Ltd | Neuroprotective effect of carotenoids in brain |
ES2800751T3 (es) * | 2016-02-22 | 2021-01-04 | Newtricious Bv | Composición para la prevención o tratamiento de enfermedades neurodegenerativas |
-
2017
- 2017-12-04 GB GBGB1720119.5A patent/GB201720119D0/en not_active Ceased
-
2018
- 2018-05-10 MX MX2020002458A patent/MX2020002458A/es unknown
- 2018-05-10 EP EP18725605.2A patent/EP3644979A1/en active Pending
- 2018-05-10 BR BR112020005132-2A patent/BR112020005132A2/pt not_active Application Discontinuation
- 2018-05-10 GB GB1807590.3A patent/GB2568986B/en active Active
- 2018-05-10 RU RU2020111305A patent/RU2020111305A/ru unknown
- 2018-05-10 AU AU2018379644A patent/AU2018379644B2/en active Active
- 2018-05-10 KR KR1020207007980A patent/KR20200095452A/ko not_active Application Discontinuation
- 2018-05-10 WO PCT/GB2018/051255 patent/WO2019110951A1/en unknown
- 2018-05-10 SG SG11202000786RA patent/SG11202000786RA/en unknown
- 2018-05-10 JP JP2020521460A patent/JP2021505527A/ja active Pending
- 2018-05-10 CA CA3071786A patent/CA3071786C/en active Active
- 2018-05-15 IE IE20180146A patent/IE87241B1/en unknown
- 2018-05-15 US US15/980,083 patent/US10835509B2/en active Active
-
2020
- 2020-01-28 ZA ZA2020/00558A patent/ZA202000558B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006116755A2 (en) * | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
JP2014524914A (ja) * | 2011-07-07 | 2014-09-25 | ハワード・ファウンデーション・ホールディングス・リミテッド | 視覚パフォーマンス及び/若しくは黄斑色素形成の改善、又は視覚パフォーマンス及び/若しくは黄斑色素形成に関連した改善 |
WO2014106741A1 (en) * | 2013-01-03 | 2014-07-10 | Howard Foundation Holdings Ltd | Identifying subjects in need of treatment |
WO2015005443A1 (ja) * | 2013-07-10 | 2015-01-15 | ライオン株式会社 | 内服組成物 |
Non-Patent Citations (1)
Title |
---|
JOHN M.NOLAN ET AL.: "The Impact of Supplemental Macular Carotenoids in Alzheimer's Disease: A Randomized Clinical Trial", JOURNAL OF ALZHEIMER'S DISEASE, vol. 44, no. 4, JPN7022000830, 19 February 2015 (2015-02-19), pages 1157 - 1169, XP055485818, ISSN: 0005213085, DOI: 10.3233/JAD-142265 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022244727A1 (ja) * | 2021-05-17 | 2022-11-24 | 小野薬品工業株式会社 | 認知機能を改善するための組成物 |
WO2024143060A1 (ja) * | 2022-12-26 | 2024-07-04 | サントリーホールディングス株式会社 | 脳神経細胞保護用組成物 |
Also Published As
Publication number | Publication date |
---|---|
GB201807590D0 (en) | 2018-06-27 |
MX2020002458A (es) | 2020-07-20 |
ZA202000558B (en) | 2021-10-27 |
RU2020111305A (ru) | 2022-01-10 |
WO2019110951A1 (en) | 2019-06-13 |
EP3644979A1 (en) | 2020-05-06 |
GB2568986B (en) | 2019-12-18 |
KR20200095452A (ko) | 2020-08-10 |
NZ761512A (en) | 2024-01-26 |
US10835509B2 (en) | 2020-11-17 |
GB2568986A (en) | 2019-06-05 |
IE20180146A1 (en) | 2019-06-12 |
GB201720119D0 (en) | 2018-01-17 |
AU2018379644B2 (en) | 2024-02-08 |
US20190167624A1 (en) | 2019-06-06 |
AU2018379644A1 (en) | 2020-03-19 |
CA3071786A1 (en) | 2019-06-13 |
IE87241B1 (en) | 2021-07-07 |
SG11202000786RA (en) | 2020-06-29 |
BR112020005132A2 (pt) | 2020-09-15 |
CA3071786C (en) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Otaegui-Arrazola et al. | Diet, cognition, and Alzheimer’s disease: food for thought | |
Mischoulon et al. | Docosahexanoic acid and ω-3 fatty acids in depression | |
ES2750365T3 (es) | Composición para el tratamiento y/o la prevención de enfermedades cardiovasculares | |
AU2011260037B2 (en) | Dietary formulations | |
Lange et al. | Diet and medical foods in Parkinson’s disease | |
JP2021505527A (ja) | 神経変性疾患の予防及び/又は治療 | |
US20140357717A1 (en) | Methods of treating hypertriglyceridemia | |
US11439614B2 (en) | Fish egg extracts, omega-3 lipid-based compositions and uses thereof | |
Demirel et al. | The metabolic effects of two different lipid emulsions used in parenterally fed premature infants—a randomized comparative study | |
US10596137B2 (en) | Medium chain fatty acids and their triglycerides for treating anxiety | |
US20200197349A1 (en) | Cognitive function | |
Ulbricht | An evidence-based systematic review of lutein by the Natural Standard Research Collaboration | |
US20190307715A1 (en) | Prevention and/or treatment of neurodegenerative disease | |
Mahmoodi et al. | Supplementation with omega-3 plus vitamin E and zinc plus vitamin C on metabolic syndrome components in postmenopausal women with type 2 diabetes | |
WO2013002404A1 (ja) | 恐怖記憶の軽減方法 | |
Reddy et al. | Interlinks between vitamin A and retinopathy | |
JP2020532580A (ja) | キサントフィルおよびオメガ−3脂肪酸を含む組成物ならびにその使用法 | |
Galvin | Medical foods and dietary approaches in cognitive decline, mild cognitive impairment, and dementia | |
Bjørkkjær et al. | A randomized double blind comparison of short-term duodenally administrated whale and seal blubber oils in patients with inflammatory bowel disease and joint pain | |
Bryan | The role of nutritional factors in cognitive ageing | |
MD | Nutritional Aspects of Cognitive Impairment | |
Kingsbury Drive | Controversies in omega-3 efficacy and novel concepts for application. | |
Page | Macular pigment optical density during pregnancy and its relationship to the diet | |
IES85984Y1 (en) | Dietary formulations | |
Mischoulon et al. | OJ-3 zyxwvutsrqp |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210510 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210510 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210519 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220301 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220530 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221004 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230302 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230929 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231114 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231115 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20231208 |